Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer

World Journal of Gastroenterology : WJG
Suo-Lin FuYing Chen

Abstract

To observe the anti-cancer effects of COX-2 inhibitors and investigate the relationship between COX-2 inhibitors and angiogenesis, infiltration or metastasis in SGC7901 cancer xenografts. Thirty athymic mice xenograft models with human stomach cancer cell SGC7901 were established and divided randomly into 3 groups of 10 each. Sulindac, one non-specific COX inhibitor belonging to non-steroidal anti-inflammatory drugs (a series of COX inhibitors known as NSAIDs) and celecoxib, one selective COX-2 inhibitor (known as SCIs) were orally administered to mice of treatment groups. Immunohistochemistry was used to examine the expression of PCNA, CD44v6 and microvessel density (MVD). Apoptosis was detected by using TUNEL assay. Tumors in sulindac and celecoxib groups were significantly smaller than those in control group from the second week after drug administration (P<0.01). In treatment group, the cell proliferation index was lower (P<0.05) and apoptosis index was higher (P<0.05) than those in control groups. Compared with the controls, microvessel density was reduced (P<0.01) and expression of CD44v6 on tumor cells was weakened (P<0.05) in treatment groups. COX-2 inhibitors have anticancer effects on gastric cancer. They play importa...Continue Reading

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T Hla, K Neilson
Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·W L XieD L Simmons
Feb 21, 2002·World Journal of Gastroenterology : WJG·Y L WuJ Y Xu

❮ Previous
Next ❯

Citations

Dec 18, 2004·Current Opinion in Rheumatology·Jorge Casas-Ganem, John H Healey
Aug 16, 2005·British Journal of Cancer·N J Bundred, N L P Barnes
May 29, 2008·Angiology·Mehmet SahinSaadet Gümüslü
Oct 29, 2011·International Journal of Cancer. Journal International Du Cancer·Alexandra ThielAri Ristimäki
Mar 29, 2014·International Journal of Molecular Medicine·Min LiuYong-Ning Zhou
Mar 20, 2018·Journal of the National Cancer Institute·Kathrin Strasser-WeipplPaul E Goss
Mar 24, 2006·Digestion·Hye Jin HwangYong Chan Lee
May 24, 2006·World Journal of Gastroenterology : WJG·Yun Dai, Wei-Hong Wang
Jun 9, 2009·Acta Cirúrgica Brasileira·Frederico Theobaldo Ramos RochaAntenor Teixeira Leal
Apr 7, 2005·Digestive Diseases·Gerardo Nardone, Alba Rocco
Apr 4, 2019·Pathology Oncology Research : POR·Lily Oguh-OlayinkaMichael J Lind
Sep 2, 2020·Cancer Metastasis Reviews·Alessandra V S FariaGwenny M Fuhler
May 6, 2015·Cancer Prevention Research·Konstantinos KatoumasAlexandra Sklavounou
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ming-Tsai LinMin-Liang Kuo
Nov 19, 2020·Clinical Journal of Gastroenterology·Alicja FormaMonika Sitarz
Apr 2, 2016·Organic Letters·Wael M Abdel-MageedXueting Liu
Dec 18, 2019·Dermatology : International Journal for Clinical and Investigative Dermatology·Khadiga Sayed SayedAya M AlOrbani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis